T0	Outcomes 0 28	Short- and long-term effects
T1	Outcomes 51 83	salivary cortisol concentrations
T2	Outcomes 323 365	hypothalamic-pituitary-adrenal (HPA) axis.
T3	Outcomes 406 460	basal diurnal and total secretion of salivary cortisol
T4	Outcomes 885 902	Salivary cortisol
T5	Outcomes 1126 1168	assess and compare cortisol concentrations
T6	Outcomes 1285 1454	impact of age, gender, body mass index (BMI), duration and severity of PD, effects of interventional time-point of the day, and levodopa doses on cortisol concentration.
T7	Outcomes 1467 1497	median cortisol concentrations
T8	Outcomes 1630 1653	Cortisol concentrations
T9	Outcomes 1786 1818	salivary cortisol concentrations
T10	Outcomes 2022 2045	cortisol concentrations
T11	Outcomes 2050 2208	age, gender, BMI, time-point for intervention, time interval between anti-parkinson pharmacy intake and sampling, levodopa doses, duration, or severity of PD.
T12	Outcomes 2221 2253	Diurnal salivary cortisol rhythm
T13	Outcomes 2266 2298	Salivary cortisol concentrations
T14	Outcomes 2497 2528	salivary cortisol concentration